Psychiatry

News

Karuna founder Daphne Zohar, now CEO of Seaport Therapeutics

Ex-Karuna team launch Seaport with $100m for psychiatry meds

The team that brought you Karuna – recently sold to Bristol-Myers Squibb for $14 billion – has set up a neuropsychiatry-focused biotech called Seaport Therapeutics.

News

Cosmo Feilding Mellen, Beckley Psytech’s chief executive

Beckley builds case for its psychedelic depression therapy

Beckley Psytech, just months away from a readout of a phase 2b trial of its psychedelic therapy for treatment-resistant depression (TRD), has built anticipation with new d

News

NICE endorses use of digital therapies for psychosis

Three digital health technologies (DHTs) used to support patients with psychosis can be used by the NHS while additional evidence of their benefits is gathered.

News

BMS completes $14bn takeover of Karuna

Bristol-Myers Squibb has got its $14 billion acquisition of Karuna Therapeutics over the line, having had to withdraw and refile antitrust paperwork and contend with a sha

News

Steve Davis, president and chief executive of Acadia Pharma

Acadia pulls trials of pimavanserin after schizophrenia fail

Acadia Pharma’s plan to develop pimavanserin as a treatment for additional indications is in disarray after the drug failed a phase 3 trial in schizophrenia.

News

Boehringer licenses Sosei schizophrenia drugs in €755m deal

Boehringer Ingelheim has taken an option on a family of compounds with potential as therapies for schizophrenia from Sosei Heptares, which it says could have broad activit

Ex-Karuna team launch Seaport with $100m for psychiatry meds

Beckley builds case for its psychedelic depression therapy

NICE endorses use of digital therapies for psychosis

BMS completes $14bn takeover of Karuna

Acadia pulls trials of pimavanserin after schizophrenia fail

Boehringer licenses Sosei schizophrenia drugs in €755m deal

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Psychiatry

Editor's Picks